MediWound Ltd. (NASDAQ:MDWD) is reporting third quarter financial results on Tuesday 10th November 2020, before market open.
According to analysts surveyed by Thomson Reuters, MDWD is expected to report 3Q20 loss of $ 0.1 per share from revenue of $ 5.79 million.
For the full year, analysts anticipate top line of $ 20.02 million, while looking forward to loss of $ 0.4 per share bottom line.
Previous Quarter Performance
MediWound Ltd. unveiled loss for the second quarter of $ 0.11 per share, from the revenue of $ 4.03 million. The consensus estimates are loss of $ 0.12 per share from $ 4.97 million in revenue. The bottom line results beat street analysts by $ 0.01 or 8.33 percent, at the same time, top line results fell short of analysts by $ 0.94 million or 18.91 percent.
Stock Performance
Shares of MediWound Ltd. traded up $ 0.11 or 2.95 percent on Monday, reaching $ 3.84 with volume of 58.90 thousand shares. MediWound Ltd. has traded high as $ 3.93 and has cracked $ 3.67 on the downward trend
According to the previous trading day, closing price of $ 3.84, representing a 159.03 % increase from the 52 week low of $ 1.44 and a 15.99 % decrease over the 52 week high of $ 4.44.
The company has a market capital of $ 104.49 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
MediWound Ltd. will be hosting a conference call at 8:30 AM eastern time on 10th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.mediwound.com
MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in Europe and Israel through its commercial organization, and Argentina and South Korea through its distributors to burn specialists treating patients with severe burns in burn centers and hospitals burn units. The company also develops EscharEx, which is in Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MWPC003 for connective tissue disorders.
